1. Home
  2. CB vs IDYA Comparison

CB vs IDYA Comparison

Compare CB & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chubb Limited

CB

Chubb Limited

N/A

Current Price

$372.89

Market Cap

143.6B

Sector

Finance

ML Signal

N/A

Logo IDEAYA Biosciences Inc.

IDYA

IDEAYA Biosciences Inc.

N/A

Current Price

$25.63

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CB
IDYA
Founded
1985
2015
Country
Switzerland
United States
Employees
N/A
145
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
143.6B
2.5B
IPO Year
1995
2019

Fundamental Metrics

Financial Performance
Metric
CB
IDYA
Price
$372.89
$25.63
Analyst Decision
Buy
Strong Buy
Analyst Count
25
15
Target Price
★ $374.87
$50.15
AVG Volume (30 Days)
★ 1.3M
1.1M
Earning Date
10-20-2026
11-03-2026
Dividend Yield
★ 1.10%
N/A
EPS Growth
13.13
★ 61.90
EPS
★ 20.46
N/A
Revenue
★ $59,402,000,000.00
$218,710,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.16
$186.04
P/E Ratio
$18.10
★ N/A
Revenue Growth
6.54
★ 3024.43
52 Week Low
$291.03
$25.75
52 Week High
$384.26
$42.68

Technical Indicators

Market Signals
Indicator
CB
IDYA
Relative Strength Index (RSI) 58.61 24.75
Support Level $317.41 N/A
Resistance Level $384.26 $29.74
Average True Range (ATR) 6.16 1.73
MACD -0.61 -0.54
Stochastic Oscillator 51.51 0.47

Price Performance

Historical Comparison
CB
IDYA

About CB Chubb Limited

ACE acquired Chubb in 2016 and assumed the Chubb name. The combination made the new Chubb one of the largest domestic property and casualty insurers, with operations in over 50 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

Share on Social Networks: